Nutriband Inc
nutriband.comWhat Do They Do?
Develops transdermal pharmaceutical products, including abuse-deterrent patches. Through its subsidiaries, provides contract manufacturing to health, wellness and over-the-counter pharmaceutical customers and contract research and development to pharmaceutical and medical-device customers.
10-K for FY2026, filed Apr 29, 2026Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the…View ↗
The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and…View ↗
Our lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic…View ↗
How Do They Make Money?
Revenue comes from sales of manufactured goods, with sales counted when products are transferred to customers; its subsidiaries also provide contract manufacturing and contract research and development services.
10-K for FY2026, filed Apr 29, 2026The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and…View ↗
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the…View ↗
Years Ending January 31, 2026 2025 Revenue by type: Sale of goods $ 2,036,651 $ 2,139,537 Services - - Total $ 2,036,651 $ 2,139,537View ↗
$2M
-
10-K for FY2026, filed Apr 29, 2026
$2M ↗
Who Are Their Customers?
Brands use the subsidiaries for manufacturing, while pharmaceutical and medical-device companies use them for research and development work.
10-K for FY2026, filed Apr 29, 2026
Do Revenues Turn Into Profits?
No. It lost $8.2M in FY2026.
10-K for FY2026, filed Apr 29, 2026
−$8.3MView ↗
10-K for FY2026, filed Apr 29, 2026
−$8.2MView ↗
10-K for FY2026, filed Apr 29, 2026
−$5.1MView ↗
How Are They Changing?
Growing. Revenue grew 43% in 4 years, from $1.4M in FY2022 to $2M in FY2026, about 9% a year.
Kindeva development arrangement
The Kindeva arrangement moved from testing whether AVERSA technology could fit its manufacturing process to commercial development and clinical supply, with shared development costs exchanged for milestone payments.
10-K for FY2023, filed Apr 26, 2023 10-K for FY2026, filed Apr 29, 2026We have a feasibility agreement with Kindeva Drug Delivery, formerly 3M Drug Delivery (“Kindeva”), for the development of AVERSA Fentanyl…View ↗
In January 2024, we signed a commercial development and clinical supply agreement with Kindeva Drug Delivery, formerly 3M Drug Delivery…View ↗
Loading...
